- AFFO/Share: Alexandria Real Estate’s Adjusted Funds From Operations (AFFO) per share for Q2 2024 was $2.36, higher than last year’s $2.24 and above the estimated $2.34.
- Revenue: The company reported revenue of $766.7 million, representing a 7.4% year-over-year increase. This was slightly below the estimated $778.3 million.
- EPS: Earnings per share (EPS) came in at 25 cents, significantly lower than last year’s 51 cents and the estimated 84 cents.
- Analyst Ratings: The stock received 14 buy ratings, 1 hold rating, and no sell ratings from analysts.
A look at Alexandria Real Estate Equities Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts predict a promising long-term future for Alexandria Real Estate Equities, as indicated by its Smartkarma Smart Scores. With a high Value score of 4 and a solid Dividend score of 4, the company is seen as offering good value and potential for income growth. However, the Growth score of 2 suggests slower growth prospects compared to other factors. Additionally, the company demonstrates a moderate level of Resilience and Momentum with scores of 3 each, indicating stability and a steady upward trend.
Alexandria Real Estate Equities, Inc. specializes in acquiring, managing, and developing office and laboratory properties primarily leased to companies in the pharmaceutical, biotechnology, and research sectors. With properties spread across key regions in the U.S., including California, Washington D.C., New England, and the Southeast, the company plays a vital role in supporting innovation and scientific advancements in these areas.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
